BioBlast Pharma Ltd. (ORPN) was a clinical-stage biotechnology company that focused on developing therapies for patients with rare and ultra-rare genetic diseases. In 2018, the company merged with Enlivex Therapeutics Ltd. to form Enlivex Therapeutics Ltd.
As of its most recent financial reports before the merger, ORPN reported a net loss of $9.3 million for the nine months ended September 30, 2017. The company had cash and cash equivalents of $12.5 million as of September 30, 2017.
BioBlast Pharma's growth strategy focused on advancing its pipeline of therapies and obtaining regulatory approval for its products. The company's focus on developing therapies for rare and ultra-rare genetic diseases has enabled it to establish a strong presence in the biotechnology industry.
Investing in clinical-stage biotechnology companies like BioBlast Pharma carries market risks, including the risk of market volatility, clinical trial setbacks, regulatory hurdles, and competition from other biotechnology providers. Investors should carefully consider these risks before investing in ORPN (now part of Enlivex Therapeutics) and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's public disclosures and financial statements to gain a better understanding of its financial performance and risks.
|
